William Blair Upgrades Sientra (NASDAQ:SIEN) to Outperform

William Blair upgraded shares of Sientra (NASDAQ:SIEN) from a market perform rating to an outperform rating in a report issued on Tuesday morning, Briefing.com Automated Import reports.

Several other brokerages have also recently issued reports on SIEN. Maxim Group reiterated a buy rating and issued a $12.00 price objective (down from $16.00) on shares of Sientra in a research note on Friday, August 9th. Canaccord Genuity set a $13.00 price objective on Sientra and gave the company a buy rating in a research note on Tuesday, September 24th. Craig Hallum reduced their price objective on Sientra from $20.00 to $14.00 and set a buy rating on the stock in a research note on Thursday, July 25th. Stephens set a $16.00 price objective on Sientra and gave the company a buy rating in a research note on Friday, August 9th. Finally, Zacks Investment Research upgraded Sientra from a sell rating to a hold rating in a research note on Wednesday, October 30th. Two research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. The company currently has an average rating of Buy and an average price target of $15.75.

Shares of NASDAQ:SIEN traded up $1.84 during midday trading on Tuesday, hitting $8.84. The company had a trading volume of 5,333,200 shares, compared to its average volume of 861,066. The stock has a market cap of $351.20 million, a price-to-earnings ratio of -2.72 and a beta of 0.24. The company has a debt-to-equity ratio of 0.18, a current ratio of 2.33 and a quick ratio of 1.99. Sientra has a twelve month low of $4.78 and a twelve month high of $19.38. The business’s 50-day simple moving average is $6.56 and its 200-day simple moving average is $6.61.

Sientra (NASDAQ:SIEN) last announced its quarterly earnings data on Thursday, November 7th. The medical instruments supplier reported ($0.45) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.47) by $0.02. The business had revenue of $22.41 million for the quarter, compared to analysts’ expectations of $20.05 million. Sientra had a negative return on equity of 123.80% and a negative net margin of 151.96%. The company’s revenue for the quarter was up 32.8% compared to the same quarter last year. During the same period last year, the firm earned ($0.72) earnings per share. As a group, sell-side analysts forecast that Sientra will post -2.42 EPS for the current year.

A number of institutional investors have recently bought and sold shares of SIEN. Point72 Hong Kong Ltd raised its stake in Sientra by 282.5% in the second quarter. Point72 Hong Kong Ltd now owns 3,997 shares of the medical instruments supplier’s stock valued at $25,000 after buying an additional 2,952 shares in the last quarter. NumerixS Investment Technologies Inc acquired a new stake in Sientra in the second quarter valued at $59,000. Private Advisor Group LLC acquired a new stake in Sientra in the second quarter valued at $62,000. Commonwealth Equity Services LLC acquired a new stake in Sientra in the third quarter valued at $84,000. Finally, Bailard Inc. raised its stake in Sientra by 28.9% in the second quarter. Bailard Inc. now owns 25,000 shares of the medical instruments supplier’s stock valued at $154,000 after buying an additional 5,600 shares in the last quarter. Institutional investors own 89.27% of the company’s stock.

Sientra Company Profile

Sientra, Inc, a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names.

Recommended Story: Discount Rate

Analyst Recommendations for Sientra (NASDAQ:SIEN)

Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.